Developing pancreatic secretory trypsin inhibitor of molecular target therapy for pancreatic cancer with pancreatic secretory trypsin inhibitor antibodies.

利用胰腺分泌性胰蛋白酶抑制剂抗体开发胰腺癌分子靶向治疗的胰腺分泌性胰蛋白酶抑制剂。

• 批准号: 23591898
• 负责人: HORINO Kei
• 金额: $ 3.41万
• 依托单位: Kumamoto University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591898/
• 关键词: 膵癌; PSTI; SPINK1; 分子標的治療薬; オートファジー; 分子標的治療

The fusion with PEG solution in the spleen cells of immunized mice and Sp2/OAg-14 cell mouse myeloma, and to confirm the presence or absence of antibody production in two weeks after the medium was replaced, it was trial and error the production of antibodies, but because it was bogged down in hybridoma create , was administered to 8 times intraperitoneally 8 weeks antigen (PSTI) to female Balb / C mice were subjected to experiments with PSTI existing monoclonal antibodies that were sensitized. Is allowed to induce pancreatitis in the administration of a single, severity was only varies with the dose.As a new function of SPINK, proceeded under study may be involved in growth promotion of pancreatic cancer via autophagy control, but woven transient in a single dose as human PSTI monoclonal antibodies - the Tofaji it was only acknowledge hyperactivity.

用PEG溶液融合免疫小鼠的脾细胞和Sp2/OAg-14细胞小鼠骨髓瘤，并确认有无抗体产生，在两周后更换培养基，这是试错抗体的产生，但由于它陷入了杂交瘤的创建，对雌性Balb / C小鼠腹腔注射8次8周抗原（PSTI），用PSTI存在的单克隆抗体进行致敏实验。SPINK作为一种新的功能，正在进行的研究可能通过自噬控制参与胰腺癌的生长促进，但作为人PSTI单克隆抗体-Tofaji在单次给药中的短暂性，它只被承认过度活跃。